{
    "clinical_study": {
        "@rank": "38562", 
        "arm_group": {
            "arm_group_label": "Ketamine arm", 
            "arm_group_type": "Experimental", 
            "description": "1. oral racemic ketamine 0.4 mg/kg"
        }, 
        "brief_summary": {
            "textblock": "This research study will determine if genetic variation in CYP2B6 affects how the body\n      metabolizes ketamine."
        }, 
        "brief_title": "CYP2B6 Polymorphisms in Ketamine", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy Volunteers", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. 18-50 yr old\n\n          2. CYP2B6*1/*1, CYP2B6*1/*6 or CYP2B6*6/*6 genotype (see table)  (Note:  subjects of\n             other rare genotype but with one or more 516G>T, 785A>G, 983T>C or 1459C>T\n             polymorphism may be enrolled at PI's discretion)\n\n          3. Good general health with no remarkable medical conditions\n\n          4. BMI <33\n\n          5. Provided informed consent\n\n        Exclusion Criteria:\n\n          1. Known history of liver or kidney disease\n\n          2. Use of prescription or non prescription medications, herbals, foods or chemicals\n             known to be metabolized by or affecting CYP2B6\n\n          3. Females who are pregnant or nursing\n\n          4. Known history of drug or alcohol addiction (prior or present addiction or treatment\n             for addiction)\n\n          5. Direct physical access to and routine handling of addicting drugs in the regular\n             course of duty (this is a routine exclusion from studies of drugs with addiction\n             potential)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01988922", 
            "org_study_id": "201307034"
        }, 
        "intervention": {
            "arm_group_label": "Ketamine arm", 
            "description": "0.4 mg/kg oral racemic ketamine", 
            "intervention_name": "ketamine", 
            "intervention_type": "Drug", 
            "other_name": "Ketalar"
        }, 
        "intervention_browse": {
            "mesh_term": "Ketamine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "ketamine polymorphisms", 
        "lastchanged_date": "May 27, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "St. Louis", 
                    "country": "United States", 
                    "state": "Missouri", 
                    "zip": "63110"
                }, 
                "name": "Washington University School of Medicine"
            }, 
            "investigator": {
                "last_name": "Evan D Kharasch, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Role of CYP2B6 Polymorphisms in Ketamine Metabolism and Clearance", 
        "overall_contact": {
            "email": "parchomj@anest.wustl.edu", 
            "last_name": "Jennifer Parchomski, RN", 
            "phone": "314-747-5164"
        }, 
        "overall_contact_backup": {
            "email": "bloodj@anest.wustl.edu", 
            "last_name": "Jane Blood, RN", 
            "phone": "314-747-5531"
        }, 
        "overall_official": {
            "affiliation": "Washington University School of Medicine", 
            "last_name": "Evan D Kharach, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "This outcome will be measured by blood draws taken during the study days and follow-ups.  This research study will determine if genetic variation in CYP2B6 affects how the body metabolizes ketamine.", 
            "measure": "The effects of CYP2B6 genetic variants on ketamine metabolism and clearance by CYP2B6*6 hetero or homozygote genotype.", 
            "safety_issue": "No", 
            "time_frame": "up to 24 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01988922"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "This outcome will be measured by blood and urine collections.", 
                "measure": "ketamine concentration", 
                "safety_issue": "No", 
                "time_frame": "up to 24 hours"
            }, 
            {
                "description": "This outcome will be measured by blood and urine collections.", 
                "measure": "norketamine formation clearances and by genotype", 
                "safety_issue": "No", 
                "time_frame": "up to 24 hours"
            }
        ], 
        "source": "Washington University School of Medicine", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Washington University School of Medicine", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}